Tenet Healthcare
THC
$273.25
+0.99%
Tenet Healthcare Corporation is a Dallas-based healthcare services organization that operates roughly 50 acute and specialty hospitals and hundreds of ambulatory surgery centers and outpatient facilities concentrated in the southern United States, supplemented by its Conifer revenue cycle management segment. The company is best characterized as a scaled, regionally concentrated hospital operator that has been repositioning itself as an ambulatory-surgery-led platform, monetizing non-core hospital assets and reinvesting proceeds into higher-margin, higher-growth outpatient capacity. The current investor narrative centers on that portfolio transformation: the July 2026 quarter delivered a sharp earnings beat and a raised full-year profit outlook, with ambulatory care revenue of $1.388 billion against $4.24 billion in hospital operations, and management has paired this with an expanded share repurchase program funded by robust free cash flow. Debate now hinges on whether the ambulatory expansion and capital-return strategy can sustain the re-rating after a roughly 30% one-year advance, particularly given a soft Q1 revenue print tied to unfavorable patient insurance mix and lingering industry-wide reimbursement and admission-mix headwinds.…
THC
Tenet Healthcare
$273.25
Related headlines
Investment Opinion: Should I buy THC Today?
Rating: Hold with a constructive bias. The core thesis is that Tenet's transformation into an ambulatory-surgery-led platform is genuinely expanding margins and generating enormous free cash flow, but after a 48.47% six-month advance the stock trades within ~6.7% of the $286.41 average analyst target, leaving little margin of safety. The consensus 'buy' rating (recommendation mean 1.57 across 22 analysts) and the $260–$315 target range anchor a view that the fundamental story is intact but largely reflected in the price.
The supporting evidence is strong: trailing free cash flow of $3.023B implies a ~16.9% FCF yield, net margin expanded to 14.68% in Q2 2026 from 6.71% in Q4 2025, operating margin stands at 18.19%, and revenue grew 6.77% YoY. Valuation is undemanding on enterprise metrics — EV/EBITDA of 6.29x and EV/Sales of 1.68x — and the stock has de-rated across PE (13.9x to 4.73x), PS (3.04x to 2.78x), and PB (4.28x to 3.35x) over the past year even as the price rose, which argues the market remains skeptical of a business that is actually improving.
The risks that could invalidate the thesis are leverage (3.12x debt-to-equity, 73.99% debt-to-capitalization), decelerating revenue with payer-mix headwinds, and sequential EBITDA softness ($1.239B in Q2 vs $1.566B in Q1). This Hold would upgrade to Buy on a pullback toward the $250 support zone (roughly -7%) or on evidence that Q3 EBITDA re-accelerates above $1.4B; it would downgrade to Sell if revenue growth falls below 5% or if buybacks are curtailed to preserve liquidity. Verdict: fairly valued to modestly undervalued on EV metrics, but fully valued on near-term analyst targets — a quality operator worth owning on weakness, not chasing at the high.
Sign up to view all
THC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $286.41 and implied upside of +4.8% versus the current price.
Average Target
$286.41
0 analysts
Implied Upside
+4.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$260 - $315
Analyst target range
Coverage is deep and overwhelmingly constructive: 22 analysts cover THC with a consensus recommendation of "buy" and a recommendation mean of 1.57 (on a 1-to-5 scale where 1 is a strong buy), and the average target price of $286.41 implies roughly 6.7% upside from the current $268.45. The Buy/Hold/Sell distribution skews heavily bullish, with the recent institutional ratings log showing a wall of reaffirmed positive ratings — Leerink at Outperform, Wells Fargo at Overweight, Truist and Guggenheim at Buy, UBS at Buy, Morgan Stanley at Overweight, TD Cowen at Buy, RBC at Outperform, and Barclays at Overweight — and only Baird sitting at Neutral. The consensus therefore leans clearly bullish, though the modest implied upside reflects that the stock has already run hard and is trading close to where the Street sees fair value. The target range runs from a low of $260.00 to a high of $315.00, a spread of about 21% around the average, which signals moderate rather than extreme disagreement among analysts. The high target of $315.00 — roughly 17.3% above the current price — would require multiple expansion on top of the raised guidance, likely assuming the ambulatory buildout accelerates, buybacks continue shrinking the share count, and EBITDA re-accelerates toward the Q1 2026 level of $1.566 billion. The low target of $260.00, about 3.1% below the current price, effectively prices in a stall in the re-rating — margin compression from unfavorable payer mix, softer admissions, or a pause in capital returns — rather than a fundamental breakdown. Notably, the consensus forward EPS estimate of $28.72 against estimated revenue of $24.085 billion implies a net margin near 10%, consistent with the recent profitability trend, and the absence of any recent downgrades despite the stock's proximity to its 52-week high suggests the Street is comfortable with the current valuation; the key catalyst to watch is whether Q3 results validate the raised guidance and push targets toward the high end of the range.
Bulls vs Bears: THC Investment Factors
The bull case currently holds the stronger evidence: margins are expanding sharply (net margin 14.68% vs 6.71% two quarters prior), free cash flow of $3.023B supports aggressive buybacks that have cut the share count ~12% year-over-year, and the stock has de-rated on every multiple even as it rallied — a signature of a market still undervaluing the fundamentals. The bear case rests on leverage (3.12x debt-to-equity, 73.99% debt-to-capitalization) and decelerating revenue growth (6.77% YoY) with payer-mix headwinds that already produced a Q1 revenue miss. The single most important tension is whether the ambulatory-surgery mix shift can keep expanding margins enough to offset a soft hospital top line and carry the EBITDA trajectory — Q2 EBITDA already slipped sequentially to $1.239B from $1.566B, so if that softness proves structural rather than seasonal, the re-rating thesis breaks. With only ~6.7% implied upside to the average target and the stock near its 52-week high, the risk/reward is balanced rather than compelling at current levels.
Bullish
- Ambulatory mix shift drives margin expansion: Q2 2026 net margin reached 14.68% ($826M net income) versus 6.71% in Q4 2025, while gross margin climbed from 15.72% to 18.19% over the same span. Ambulatory care revenue of $1.388B is the strategic engine management is deliberately scaling, and mix shift toward higher-margin outpatient volume supports both earnings durability and multiple expansion.
- Massive free cash flow and buyback firepower: Trailing twelve-month free cash flow of $3.023B against a ~$17.9B market cap implies an FCF yield near 16.9%, unusually high for a levered hospital operator. Management deployed $1.042B of buybacks in Q2 2026 alone after $318M in Q1, shrinking diluted shares from 95.0M in Q1 2025 to 83.96M in Q2 2026 — a roughly 12% reduction that mechanically lifts EPS.
- Deep, overwhelmingly bullish analyst coverage: 22 analysts carry a consensus 'buy' with a recommendation mean of 1.57, and the average target of $286.41 implies ~6.7% upside from $268.45. The ratings log shows a wall of reaffirmations — Leerink Outperform, Wells Fargo Overweight, Morgan Stanley Overweight, UBS Buy — with only Baird at Neutral and no recent downgrades despite the stock sitting near its 52-week high.
- Valuation de-rated even as price rose: PE compressed from 13.9x at Q2 2025 to 4.73x at Q2 2026, PS from 3.04x to 2.78x, and PB from 4.28x to 3.35x — earnings and book value have grown faster than the share price. EV/EBITDA of 6.29x and EV/Sales of 1.68x are modest for a business growing revenue 6.77% with an 18.19% operating margin, leaving room for multiple expansion.
Bearish
- Heavy leverage is the core fundamental risk: Debt-to-equity stands at 3.12x, total debt to capitalization at 73.99%, and the equity multiplier at 6.59x, making the equity a leveraged claim on EBITDA. Interest expense of $204M per quarter (~$816M annualized) consumes a meaningful share of the $1.239B Q2 EBITDA, leaving the business sensitive to rate and refinancing conditions.
- Revenue growth decelerating with payer-mix headwinds: Q2 2026 revenue growth of 6.77% YoY ($5.628B vs $5.271B) has moderated from earlier periods, and the Q1 2026 revenue shortfall was explicitly blamed on unfavorable patient insurance mix. A soft top line combined with industry-wide reimbursement and admission-mix pressure threatens the earnings trajectory that justifies the current re-rating.
- EBITDA sequentially soft and buyback-dependent EPS: Q2 2026 EBITDA of $1.239B (22.01% margin) fell from $1.566B in Q1 2026 (29.17% margin), a notable sequential decline. With $1.36B of buybacks in the first half of 2026, investors should question whether EPS growth is being driven by share-count reduction rather than underlying operating improvement.
- Limited analyst upside after the run: The average target of $286.41 implies only ~6.7% upside, and the low target of $260.00 sits 3.1% below the current $268.45 — meaning the Street's downside case is essentially flat. With the stock up 48.47% in six months and trading near its 52-week high of $283.05, much of the raised-guidance thesis appears already priced in.
THC Technical Analysis
THC is in a sustained, powerful uptrend: the stock is up 29.74% over the past year, 34.60% year-to-date, and 48.47% over six months, with the current price of $268.45 sitting at roughly 88% of its 52-week range of $157.58 to $283.05. That positioning near the upper end of the range confirms persistent momentum rather than a mean-reversion setup, though it also leaves limited room before the stock tests its 52-week high and raises the risk of profit-taking after such an extended advance. The relative strength versus SPY is emphatic across every window — +16.61 percentage points over one year, +23.15 YTD, and +42.02 over six months — underscoring that this is a market leader, not a beta-driven laggard. Recent momentum remains constructive but has decelerated from its spring pace: the stock is up 4.68% over the past month and 15.12% over three months, a marked slowdown from the 48.47% six-month gain that was driven largely by the explosive late-July move from $199.02 on July 23 to $233.20 on July 24 and $262.63 by July 28. That one-month gain of 4.68% also compares favorably to SPY's -1.02%, a 5.70-point relative outperformance, indicating the consolidation since the August peak near $280.77 is orderly rather than distributive. The stock has spent roughly two months chopping between the high-$240s and low-$270s, digesting the post-earnings gap, and the absence of a breakdown despite that consolidation is a sign of demand absorption rather than exhaustion. Key levels are well defined: resistance sits at the 52-week high of $283.05, and a decisive breakout above that level — ideally on volume above the current 459,896-share session — would signal a fresh leg higher and validate the raised-guidance thesis, while support rests at the 52-week low of $157.58, with intermediate support in the $249-$250 area where the stock found buyers in late September. A beta of 1.199 means the stock is roughly 20% more volatile than the market, which warrants modestly smaller position sizing and wider stops; the maximum drawdown of -34.08% over the trailing period is a reminder that this name can correct sharply even within a secular uptrend, so risk management around the $250 support zone is essential.
Beta
1.20
1.20x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$158-$283
Price range past year
Annual Return
+31.0%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | -0.9% |
| 3m | +7.2% | +1.2% |
| 6m | +49.1% | +4.9% |
| 1y | +31.0% | +11.2% |
| ytd | +37.0% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Revenue is growing at a solid but moderating clip: Q2 2026 revenue of $5.628 billion rose 6.77% year-over-year from $5.271 billion in Q2 2025, extending a multi-quarter expansion from $5.223 billion in Q1 2025 and $5.527 billion in Q4 2025. The sequential trajectory is healthy — $5.368 billion in Q1 2026 to $5.628 billion in Q2 2026 — but the growth rate has decelerated from the double-digit pace implied by earlier periods, and the Q1 2026 revenue shortfall attributed to unfavorable patient insurance mix remains a watch item. Segment data shows ambulatory care at $1.388 billion versus $4.24 billion in hospital operations, meaning the outpatient business is roughly a quarter of the total but is the strategic growth engine management is deliberately scaling through acquisitions and de novo buildouts. The investment case therefore rests less on headline revenue acceleration and more on mix shift toward higher-margin ambulatory volume, which should support both growth durability and multiple expansion if executed. Profitability is strong and improving: Q2 2026 net income reached $826 million on a 14.68% net margin, up from $702 million and a 13.08% margin in Q1 2026 and $371 million and a 6.71% margin in Q4 2025, while operating income of $1.024 billion equates to an 18.19% operating margin. Gross margin of 18.19% in Q2 2026 expanded from 16.43% in Q1 2026 and 15.72% in Q4 2025, and the company-level gross margin of 82.26% in the valuation data reflects a different cost-of-revenue classification but confirms a high-margin, services-heavy cost structure typical of hospital operators. EBITDA of $1.239 billion in Q2 2026 (a 22.01% EBITDA margin) versus $1.566 billion in Q1 2026 shows some sequential softness, but the trailing profitability trend — ROE of 33.34% and ROA of 8.32% — is well above what is typical for capital-intensive acute-care operators and reflects both operational leverage and the earnings boost from buybacks reducing the share count. Balance sheet leverage is the principal fundamental risk: debt-to-equity stands at 3.12x, total debt to capitalization at 73.99%, and the equity multiplier at 6.59x, meaning the business is heavily levered and sensitive to rate and refinancing conditions. Liquidity is adequate — a current ratio of 1.76x and cash of $2.17 billion at Q2 2026 — and cash generation is the offsetting strength, with trailing twelve-month free cash flow of $3.023 billion and Q2 2026 FCF of $417 million after $168 million of capex, though quarterly FCF is lumpy ($1.461 billion in Q1 2026 versus $367 million in Q4 2025). Management is deploying that cash aggressively into buybacks — $1.042 billion repurchased in Q2 2026 alone, following $318 million in Q1 2026 — which supports EPS but also means external financing capacity and covenant headroom matter; the FCF yield of roughly 16.9% on the $17.9 billion market cap is high for a levered hospital operator and provides a genuine cushion, but investors should monitor whether buyback-funded EPS growth masks underlying EBITDA stagnation.
Quarterly Revenue
$5.6B
2026-06
Revenue YoY Growth
+6.8%
YoY Comparison
Gross Margin
18.2%
Latest Quarter
Free Cash Flow
$3.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Because Tenet is profitable — Q2 2026 net income of $826 million and trailing EPS of $9.89 — the PE ratio is the appropriate primary metric, and the stock trades at 12.73x trailing earnings and 12.73x forward earnings, an essentially identical trailing-to-forward multiple that implies the market is not pricing in meaningful EPS growth from current levels. That flatness is notable given the consensus forward EPS estimate of $28.72, which is far above the $9.89 quarterly figure and suggests the trailing multiple may be distorted by one-time items or a different EPS basis; on the forward estimate, the implied multiple is dramatically lower, which would make the stock look inexpensive if that earnings power is realized. The EV/EBITDA of 6.29x and EV/Sales of 1.68x are the more reliable cross-checks for a levered, capital-intensive operator and both sit in reasonable territory for the hospital sector. Against the sector, the picture is mixed: a PS ratio of 0.84x and EV/Sales of 1.68x are modest for a healthcare services company with 6.77% revenue growth and an 18.19% operating margin, while the PB ratio of 4.25x is elevated — a direct consequence of the 3.12x debt-to-equity leverage and thin book equity rather than a premium growth multiple. The PEG ratio of -0.24 is not meaningful given the sign distortion and should be disregarded. On balance, the stock does not screen as expensive on earnings or sales multiples relative to its growth and margin profile, but the leverage-adjusted PB and the heavy debt load mean the equity is a leveraged claim on EBITDA, so the EV-based multiples are the honest lens. Historically, Tenet's PE has compressed dramatically from the 13.9x recorded at Q2 2025 and 13.0x at Q3 2025 to 4.73x at Q2 2026, while the PS ratio has moved from 3.04x at Q2 2025 to 2.78x at Q2 2026 and the PB from 4.28x to 3.35x — a broad de-rating across every multiple even as the stock price rose, which means earnings and book value have grown faster than the share price. That is the signature of a stock the market still values skeptically despite strong fundamentals, and it argues that the current valuation sits near the low end of its own historical band rather than at an optimistic extreme, leaving room for multiple expansion if the ambulatory strategy and capital returns continue to deliver.
PE
12.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the balance sheet. Debt-to-equity of 3.12x, total debt to capitalization of 73.99%, and an equity multiplier of 6.59x mean the equity is a thin claim on a heavily levered enterprise, and quarterly interest expense of $204M absorbs roughly 16% of Q2 2026 EBITDA of $1.239B. EBITDA itself softened sequentially from $1.566B in Q1 2026 to $1.239B in Q2, and quarterly free cash flow is lumpy ($1.461B in Q1 versus $367M in Q4 2025), so the $1.042B Q2 buyback was partly funded from a strong prior quarter rather than run-rate cash generation. Revenue concentration in hospital operations ($4.24B of the $5.628B total) means the ambulatory growth engine — only $1.388B — must scale quickly to offset any acute-care softness, and the Q1 2026 payer-mix shortfall shows how quickly a single variable can dent the top line.
Market and competitive risks are dominated by valuation compression and sector dynamics. The stock trades at 12.73x trailing and forward earnings — an essentially identical trailing-to-forward multiple that implies the market expects no meaningful EPS growth — while the PB of 4.25x is elevated purely because of leverage rather than a growth premium. A beta of 1.199 means roughly 20% more volatility than the market, so any rotation out of healthcare services or a rate-driven de-rating of levered operators would hit THC disproportionately. Recent news flow is supportive — Zacks highlighted the cash-flow-backed capital-return strategy and the raised guidance — but the Q1 admission-mix issue flagged by Benzinga remains an industry-wide reimbursement headwind that could resurface in any quarter.
Worst-case scenario: a combination of payer-mix deterioration compressing hospital margins, ambulatory buildout costs running ahead of revenue, and a pause in buybacks would force the market to re-underwrite the leverage. In that chain, EBITDA reverting toward the Q4 2025 level of $1.117B while the EV/EBITDA multiple compresses toward 5x would pressure the equity sharply given the 6.59x equity multiplier. Quantitatively, the 52-week low of $157.58 represents a -41.3% decline from the current $268.45, and the trailing maximum drawdown of -34.08% implies a realistic adverse move to roughly $177. The analyst low target of $260.00 (-3.1%) is far too benign to represent a true worst case; investors should size positions assuming a -35% to -41% downside is possible if the margin story breaks.
FAQ
The most severe risk is balance-sheet leverage: debt-to-equity of 3.12x, total debt to capitalization of 73.99%, and a 6.59x equity multiplier mean a modest EBITDA decline translates into outsized equity damage, with $204M of quarterly interest expense already consuming ~16% of Q2 EBITDA. Second is revenue and payer-mix risk — Q2 growth decelerated to 6.77% YoY and the Q1 2026 miss was blamed on unfavorable patient insurance mix, a headwind that could recur. Third is earnings-quality risk: Q2 EBITDA fell sequentially to $1.239B from $1.566B, and $1.36B of H1 buybacks raise the question of whether EPS growth is buyback-driven rather than operational. Fourth is valuation/momentum risk — with only ~6.7% upside to the average target and a 1.199 beta, a sector rotation or profit-taking after the 48.47% six-month run could push the stock toward the $249–$250 support zone or the -34.08% max-drawdown scenario.
The 12-month outlook splits into three scenarios. The base case (55% probability) targets $270–$290, assuming results track the raised guidance, revenue grows mid-single digits, and the stock converges on the $286.41 average analyst target. The bull case (25%) targets $300–$315, requiring EBITDA to re-accelerate above $1.4B, continued buybacks, and a breakout above the $283.05 52-week high toward the $315 analyst high. The bear case (20%) targets $200–$250, driven by payer-mix deterioration, EBITDA falling below $1.1B, and a retest of the $249–$250 support zone. The base case is most likely, and its key assumption is that margins hold near Q2 levels (18.19% gross, 14.68% net) as ambulatory mix offsets hospital softness — a break in that assumption shifts probability toward the bear case.
THC screens as fairly valued to modestly undervalued on enterprise metrics but fully valued on near-term targets. EV/EBITDA of 6.29x and EV/Sales of 1.68x are modest for a business with 6.77% revenue growth and an 18.19% operating margin, and the stock has de-rated across every multiple over the past year — PE from 13.9x to 4.73x, PS from 3.04x to 2.78x, PB from 4.28x to 3.35x — even as the price rose, meaning fundamentals have outpaced the share price. The 12.73x trailing and forward PE are essentially identical, implying the market expects no meaningful EPS growth, which looks conservative against the $28.72 consensus forward EPS estimate. However, the 4.25x PB is elevated purely because of the 3.12x debt-to-equity leverage and thin book equity, not a growth premium. Net: the market is paying a fair-to-discounted price on cash flow and EBITDA, with upside if the ambulatory margin story continues to deliver.
From a risk/reward standpoint, THC is a reasonable but not compelling buy at $268.45. The average analyst target of $286.41 implies only ~6.7% upside, while the 52-week low of $157.58 represents -41.3% downside and the trailing max drawdown of -34.08% shows the stock can correct sharply. The fundamental case is genuinely strong — 14.68% net margin, $3.023B trailing FCF, and a 6.29x EV/EBITDA — but with the stock up 48.47% in six months and near its 52-week high of $283.05, much of the good news is priced in. It is a better buy on a pullback toward the $250 support zone, where the risk/reward improves materially. For patient investors comfortable with 1.199 beta volatility and leverage risk, accumulating on weakness makes more sense than chasing at current levels.
THC is best suited to a medium-to-long-term holding period of at least 12–18 months, though it can support tactical short-term trades around catalysts. It pays no dividend (0% yield, 0% payout ratio), so total return depends entirely on price appreciation and buyback-driven EPS growth, which favors a patient horizon that lets the ambulatory transformation compound. The 1.199 beta and -34.08% trailing max drawdown mean short-term holders face meaningful volatility — the +32% four-session move from $199.02 to $262.63 in late July shows how violently it can gap on earnings. Earnings visibility is reasonably good given the raised guidance and 22-analyst coverage, but the leverage profile argues against a buy-and-forget approach. A concrete suggestion: a minimum 12-month holding period with position sizing reduced for the beta, and a stop discipline around the $249–$250 support zone for anyone trading the shorter-term momentum.